MIME-Version: 1.0 Content-Type: multipart/related; boundary="----=_NextPart_01DA0328.07D362C0" This document is a Single File Web Page, also known as a Web Archive file. If you are seeing this message, your browser or editor doesn't support Web Archive files. Please download a browser that supports Web Archive. ------=_NextPart_01DA0328.07D362C0 Content-Location: file:///C:/14635B32/AgboezeNMJ64No4Page582.htm Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
<=
/td>
Hepatitis B Virus Seroprevalence and Poten=
tial
Perinatal
Transmission Among Pregnant Women in Abakaliki, Nigeria.
*Joseph Agboeze1,
Nwali Matthew Igwe1, Chukwuemeka Ikechi Ukaegbe1
Background: Hepatitis B =
Virus
Hepatitis B Virus (HBV) infection is a global public health problem. It is
highly endemic in Nigeria and it is estimated th=
at
about 9-12% of the total population of Nigeria are chronic carriers of
hepatitis B surface antigen.
Epidemiological data on (HBV)infection among pregnant women in Niger=
ia
are very scarce, especially in rural areas. The purpose of this study was t=
o determine
the prevalence and potential perinatal transmission among rural pregnant wo=
men
in Abakaliki Nigeria.
Methods=
: A cross-sectional study was conducted among pregnant wom=
en accessing
antenatal care at the Federal Teaching Hospital, Abaka=
liki. We consecutively recruited 300
pregnant women attending antenatal consultations. A pretested questionnaire=
was
used to collect socio-demographic data and factors associated with HBV
infection. The presence of hepatitis B surface antigen (HBsAg), hepatitis B=
e antigen
(HBeAg), and human immunodeficiency virus (HIV)=
were
determined using commercial test strips. A chi-square t=
est
was used for the analysis.
Results: The mean age=
was
31.8 (SD6.2) years. All women were married and (23.4%) were farmers while
(47.0%) had secondary education. Sixteen women (5.3%) were HBsAg-positive, =
of
whom (6.3%) were positive for HBsAg. The prevalence of HIV infection was
(0.3%). Overall, (6.3%) women were co-infected with HIV and HBV. Independent
correlates of HBV infection included a history of Jaundice
(p =3D 0.046) history of sexually transmitted infections (p=3D0=
.005)
and concurrent infection by HIV (p < 0.0001).
Conclusion: The prevalence of HBV infection among
pregnant women in Abakaliki was intermediate. T=
he
relatively high rate of women positive to both HBsAg and HBeAg
suggests that perinatal transmission of HBV might be the prevailing mode of=
HBV
transmission in this area.
Keywords: Hepatitis B =
virus
HBsAg, HBeAg Pregnancy Nigeria
=
*Correspondence: Dr Joseph
This is an open access journal, and articles are distributed und=
er
the terms of the Creative Commons Attribution-Non-Commercial-Share Alike 4.0
License, which allows others to remix, tweak, and build upon the work
non-commercially, as long as appropriate credit =
is given,
and the new creations are licensed under the identical terms.
How to cite this article<=
span
lang=3DEN-GB style=3D'font-size:9.0pt;font-family:"Times New Roman",serif;
mso-ansi-language:EN-GB'>: Agboeze J, Nwali MI,=
Ukaegbe CI. Hepatitis B Virus Seroprevalence and Pote=
ntial
Perinatal Transmission Among Pregnant Women in Abakali=
ki,
Nigeria. Niger Med J 2023;64(4):582-590. Accepted: September 5, 2023. Published: September 21, 2023.
&sh=
y;
Introduction
Background
Hepatitis B =
Virus
infection is a global public health problem. More than one-third of the wor=
ld
population has been reported to have serological evidence of past or present
hepatitis B virus (HBV) infection1,2,3. It is estimated that 350
million people globally are chronic carriers of hepatitis B virus of whom 1=
70
million reside in Africa 2,3. Areas of particularly high endemic=
ity
are in Sub-Saharan Africa and Asia 4-8. It is highly endemic in
Nigeria and about 9-12% of the total population of Nigeria are chronic carr=
iers
of hepatitis B surface antigen4,6,9. Hepatitis B Virus (HBV)
infection is an important cause of liver disease in pregnancy. The
seroprevalence of hepatitis B surface antigen (HBsAg) in pregnant women ran=
ges
from 0.67% in Spain10 to 37% in Papua New Guinea11. In
Port Harcourt, Nigeria, the seroprevalence of hepatitis B surface marker in
pregnant women is 4.3% 4 whereas, in Ghana and Kenya, the hepati=
tis
B surface antigen (HBsAg) seroprevalence in pregnant women is 6.4%12=
sup>
and 9.3% 2 respectively.
Mother-to-child
transmission (MTCT) of HBV is responsible for m=
ore
than one-third of chronic HBV infections globally 13. Indeed,
perinatal transmission seems to be predominant in high-prevalence areas suc=
h as
sub-Saharan African countries 14. Children born to mothers posit=
ive
for hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) have a 70-90% likelihood of perinatal acquisit=
ion of
HBV infection, and up to 90% of perinatal infections evolve towards chronic=
ity
compared to nearly 5% of adult infections 15. Prevention of
perinatal transmission of HBV is therefore crucial to tackling the burden of
the disease in high-endemic sub-Saharan African areas. Effective strategies=
for
reducing the incidence of chronic infections include maternal screening
combined with post-exposure prophylaxis consisting of HBV vaccination
immediately after delivery in all children born to HBsAg-positive mothers,
ideally with immunoglobulin prophylaxis 16. This study aimed to
determine the prevalence and factors associated with HBV infection and the
infectivity of rural pregnant women in the Far North region of Cameroon.
Methods,
Questionnaire administration, Laboratory testing, Statistical analysis, and
finally Ethical considerations.
Study
design
This
was a cross-sectional study conducted among pregnant women accessing antena=
tal
care or delivery services at the Federal Teaching Hospital, Abakaliki.
Study
setting and population.
The
hospital is located in the =
Abakaliki
Metropolis, the capital of Ebonyi State of Nigeria. The inhabitants are mai=
nly
the Igbos. The majority of<=
/span> the population dwells in rural areas with farming as=
their
major occupation17. The study population comprised all
pregnant women who attended antenatal care at the Federal Teaching Hospital
during the study period.
Sampling
technique and sample size
The
prevalence rate of Hepatitis B surface antigen (HBsAg) in pregnant women in
Enugu is 4.5%1. This prevalence rate of 4.5% has been chosen to
calculate the minimum sample size of this study. This is because Enugu and =
Abakaliki fall under the same South-East Geopolitical=
zone
of Nigeria with similar socio-cultural and demographic characteristics and =
no
such studies have been done in Ebonyi state.
The
minimum sample size for this study therefore will be calculated using the
following equation18.
n
=3D Z2PQ/d2
n
=3D The minimum sample size
z
=3D The standard normal deviate =3D 1.96
p
=3D The proportion in the target population estimated to have a particular
characteristic with a prevalence rate of 4.5%1 (0.045) in this
instance
q
=3D 1.0 – p =3D which is 1.0 – 0.045 =3D 0.955
d
=3D Degree of accuracy desired which is 2.5% (0.025) in this case.
Consequently,
by applying the formula as follows:
n
=3D (1.96)2 x 0.045 x 0.957 =3D 3.8416 x 0.045 x 0.955 =3D 0.165=
0928 =3D
264.15
&=
nbsp; &nbs=
p; (0.025)2 &=
nbsp; &nbs=
p; &=
nbsp; 0.000625 &=
nbsp;
The
minimum sample size was 264, allowing for a 20% attrition rate, the sample =
size
for this study was 300.
Data
collection and laboratory investigation.
A
structured pretested questionnaire was used to collect socio-demographic
information and data on risk factors for HBV infection among participants. =
Upon
completion of the questionnaire, 5 ml of venous blood was aseptically
collected by venipuncture into an Ethylene Di-amine Tetra-acetic Acid (EDTA)
tube. The plasma obtained from each sample was tested for the presence of H=
BsAg
using a commercial test strip, the Clinotech
Diagnostics HBsAg detection test according to the manufacturer’s
instructions. All samples tested positive were retested for confirmation us=
ing
the same kit. There were no discordant results. Samples confirmed positive =
for
HBsAg were further tested for HBeAg using a
commercial test strip, the Clinotech Diagnostic=
s HBeAg detection test. We also tested all blood sample=
s for
HIV according to the national screening algorithm. Accordingly, samples were
first screened with an anti-HIV antibody rapid test, the Determine HIV-1/2
(Abbott Laboratories, IL, USA).
Data
analysis
Data
were entered and analyzed using Epi info for Windows, version 7. (Atlant=
a,
GA 30329-4027 USA). Results are presented as counts
(proportions) and mean with standard deviations (SD). The influence of vari=
ous
factors on the occurrence of HBV infection was calculated by both univariate
and bivariate analyses. A p-value < 0.05 was set as
statistically significant.
Ethical
consideration
Formal
approval was obtained from the Research and Ethics Committee of the Federal
Teaching Hospital, Abakaliki with reference no
FMC/AI/AD/05/227. The participation of any pregnant woman in this study was
voluntary and only after written informed consent had been obtained. Those recruited were free to withdraw from the study =
at any
point in this study without any influence on their continued management in =
the
hospital. An arrangement was made for those who had positive HBeAg to obtain treatment at the Federal Teaching Hos=
pital Abakaliki at no cost to them.
Results
A
total of 300 pregnant women receiving antenatal care at Federal Teaching
Hospital Abakaliki were serially recruited into=
this
study.
The
age ranged from 20 to 48 years with a mean age of 31.9 ± 6.3 years. =
The majority of the women were in the age group 21-30 =
years
149 (49.7%). Most of our respondents 141 (47%) had secondary school educati=
on
and 83 (27.7%) women were Farmers.
(Table 1)
Table 1 Demographics=
of
pregnant women attending antenatal care in the Federal Teaching Hospital Abakaliki, Ebonyi state. Nigeria.2014
Variables |
Number
(N=3D300) |
Percentage
(%) |
Age |
|
|
≤
20 |
5 |
1.7 |
21-30 |
149 |
49.7 |
31-40 |
115 |
38.3 |
41-50 |
31 |
10.3 |
Educational
level |
|
|
None |
35 |
11.7 |
Primary |
51 |
17 |
Secondary |
141 |
47 |
Tertiary |
73 |
24.3 |
Marital
Status |
|
|
Married |
300 |
100 |
Occupation |
|
|
Farmer |
83 |
27.7 |
Civil
servants |
72 |
24 |
Students |
69 |
23 |
Traders |
62 |
20.6 |
Unemployed |
14 |
4.7 |
Risk
factors for HBV infection are presented in Table 2 The main factors
reported were: previous history of sexually transmitted infection (68.0%),
previous history of jaundice (35.3%), and family history of known HBV infec=
tion
(6.5%).
Characteristics |
NO |
Percentage
(%) |
Yes |
Percentage
(%) |
Risk
factors |
|
|
|
|
Previous history of Jaundice; |
194 |
64.7 |
106 |
35.3 |
History of tattoo; <= o:p> |
297 |
99 |
3 |
1 |
History of Sexually<=
span
style=3D'mso-spacerun:yes'> transmitted
infection; |
96 |
32 |
204 |
68 |
Family
history of hepatitis |
252 |
84 |
48 |
16 |
Past history of
abortion |
280 |
93.3 |
20 |
6.7 |
Number
of pregnancies < 4 |
83 |
27.7 |
217 |
72.3 |
HIV
serology test |
299
(Negative). |
99.67 |
1
(Positive) |
0.33 |
The
prevalence of HBV infection was 5%.
Factors
independently associated with HBV infection included previous history of
Jaundice (p =3D 0.046) History of sexually transmitted infectio=
ns (p
=3D 0.005) and co-infection with HIV (p < 0.001). The other
factors assessed did not influence the occurrence of HBV infection among our
participants (Table 3).
Table 3. Correlates o=
f HBV
infection among pregnant women attending antenatal in the Federal Teaching
Hospital Abakaliki, Ebonyi State. Nigeria. 2014
Variables |
Hepatitis
B Negative |
Hepatitis
B Positive |
P-value |
Age |
|
|
|
≤31 |
144
(50.7%) |
10
(62.5%) |
0.508 |
≥32 |
140
(49..3%) |
6
(37.5%) |
|
Educational
Level |
|
|
|
Below
Secondary |
77(72.89%) |
6(37.5%) |
0.537 |
Secondary
& above |
207(27.77%) |
10(62.5%) |
|
Parity |
|
|
|
≤4 |
236(83.10%) |
13(81.25%) |
0.880 |
≥5 |
48(16.90%) |
3(18.75%) |
|
History
of tattoo |
|
|
|
Yes |
2(0.7%) |
1(6.25%) |
0.380 |
No |
282(99.3%) |
15(93.75%) |
|
HIV
status |
|
|
|
positive |
0(0.00) |
1(6.25%) |
0.046 |
Negative |
284(100%) |
15(93.75%) |
|
History
of jaundice |
|
|
|
Yes |
106(37.32%) |
0(0.00%) |
0.005 |
No |
178(62.68%) |
16(100%) |
|
History
of hepatitis |
|
|
|
Yes |
48(16.90%) |
0(.0.00%) |
0.148 |
No |
236(83.10%) |
16(100.0%) |
|
History
of STI |
|
|
|
Yes |
200(70.42%) |
4(25.0%) |
0.001 |
No |
84(29.58%) |
12(75.0%) |
|
History
of miscarriage |
|
|
|
Yes |
35 |
1 |
0.768 |
No |
265 |
15 |
|
Discussion
We
investigated the seroprevalence and factors associated with HBV infection i=
n Abakaliki Nigeria. The information gathered by this w=
ork
may contribute to improving knowledge of HBV infection epidemiology in preg=
nant
women in that region and inform local and national antenatal HBV screening =
and
infant immunization policies.
In
this study seroprevalence of HBV infection among pregnant women attending t=
he
antenatal clinic at the Federal Teaching Hospital, Aba=
kaliki
Nigeria was 5%. The prevalence reported in our study is consistent with data
reported among pregnant women in Nigeria: 4.5% in Enugu1,4.3%
reported in Port Harcourt 4,2.19 % reported in Benin City,1=
9 and
5.7% reported in Ilorin20. However, the prevalence rate was
lower,11.6% in Maiduguri21, 8.3% in Zaria22and 11% in
Makurdi23 in Nigeria. The various data reported among pregnant w=
omen
in sub-Saharan African countries: 6.5% in Congo 24, 9.3% in Keny=
a 25,
9.5% in Gabon 26, 10.7% in Burkina Faso 27, 10.9 % in
Mauritania 28, 12.6% in Ghana 29, 13.8% in Senegal 30,
and 25% in Zimbabwe 31. The seroprevalence of HBV in Nigeria is
higher in northern Nigeria than in the southern part of the country where t=
his
study was done. Reasons deduced for this difference include poor awareness =
of
the infection and misconception about the safety of immunization which is a
common finding in Northern Nigeria. Also, the common practice of Polygamy a=
nd
widespread practice of native scarification in Northern Nigeria could
contribute to the high prevalence in Northern Nigeria1,4,8. The
practice of scarification and tattooing has been reported to play a role in
hepatitis B Virus infection.19
The
age group of 21-30 years had the highest prevalence of 49.7% in this study =
This
agrees with the findings in Port Harcourt4 but is in contrast to=
the
observations in the Middle East and Indonesia where most of the subjects we=
re
between 30 and 40 years of age 19.The preponderance of
HBsAg–positive pregnant women in this age bracket could be due to the
fact that women within this age bracket constitute the majority of our
obstetric population.
Mother-to-child
transmission (MTCT) of HBV is reported to be
responsible for more than one-third of chronic HBV infections globally 13,
and prenatal infection is assumed to be a major mode of transmission in
high-prevalence areas like most sub-Saharan African countries 14=
. HBeAg positivity is associated with a high risk of
perinatal transmission of HBV as children born to mothers positive to both
HBsAg and HBeAg have a 70-90% chance of perinat=
al
acquisition of HBV infection 15. The HBsAg seroprevalence rate in
this study was 6.3%. This finding is higher than 3.3% in Makurdi23
and 1.36% in Maiduguri8. The prevalence rate from this study is =
also
significantly higher than 0.8%21 reported in Zimbabwe. In studies
done at Port Harcourt and Enugu, HBsAg seropositive subjects were not tested
for HBeAg. HBeAg an=
d viral
DNA level determine the level of mother-to-child transmission of HBV.3=
3
Hence for those reactive to HBeAg, the possibil=
ity of
mother-to-child transmission is high. The overall prevalence of =
HBeAg in our sample was 0.33%. This suggests that the
probability of HBV MTCT was high in our study
population.
The
prevalence of HIV/HBV co-infection was 6.3%. This co-infection rate was hig=
her
than the 4.2% rate reported in a study in Nigeria 34. We found t=
hat
HIV infection was highly associated with HBV infection in our study populat=
ion,
this can be explained by the fact that HBV and HIV share common modes of
transmission. Moreover, it has been reported that HIV/HBV co-infection
facilitates HBV replication and reactivation leading to higher HBV-DNA leve=
ls
and a reduced spontaneous clearance of the virus35.
This
study was limited by certain factors. First, we used rapid diagnostic tests
which are less sensitive than ELISA or PCR tests, leading to possible
underestimation of the prevalence of assessed markers. Furthermore, we
investigated HBV infectivity based only on HBeAg, and
we did not look for HBV viral load which is an important determinant of HBV
transmission. Despite these shortcomings, this study provides relevant
information in the context of very limited epidemiological data on HBV
infection in Nigeria, especially among pregnant women.
Conclusion and Recommendation
The
seroprevalence of HBsAg among pregnant women in our setting is intermediate.
History of jaundice, History of sexually transmitted infection, and HIV
infection are independently associated with the occurrence of HBV infection=
in
this setting. In view of this, routine testing of all pregnant women for HB=
sAg
is necessary. Routine vaccination of all infants, irrespective of maternal =
HBV
carrier status, as it is currently practiced, is also an effective approach=
to
HBV prevention and control in Abakaliki, Nigeri=
a and
this practice should be continued and enforced.
References
=
1. Obi
S. N: Onah H. E: Ezugwu F. O. Risk factor for hepatitis B infection during
pregnancy in a Nigerian obstetric population. Journal of obstetrics and Gynecology;=
i>
2006; 26(8): 770-772.
=
2. Okoth
Mkbttia J, Gathesen=
Z, Marila
F, Mogo F, Esamai F, Alavi Z, Otieno Y, Lambatt H, Wanjaki N.
Seroprevalence of hepatitis B markers in pregnant women in Kenya. East Afr m=
ed
Journal. 2006; 38(9): 485-=
39.
=
3. Kane
M. Global Programme for the control of hepatitis B infection. Vaccine: 1995=
; 13
(supp); 544-549.
=
4. Akani CI, Ojule AC, Opurum<=
/span> HC. Ejilemele AA. =
Seroprevalence
of hepatitis B surface antigen (HBsAg) in pregnant women in port Harcourt
Nigeria. The Nigerian postgraduate
Medical Journal. 2005: 12(=
4):
266-267
=
5. Abia-bassey LN. Seropositivity of B virus among Health care
workers, In Calabar Nigeria. Mary S=
lessor
Journal of Medicine 2006 6=
(2):
36-39.
=
6. Ejele
O. Nwauche CA Erabor O. The Prevalence of hepat=
itis B
surface antigenaemia in HIV positive patients i=
n the
Niger Delta. Nigeria. Nigerian Jour=
nal of
medicine: 2004; 13(2): 175=
-9:
=
7. Anya
SE, Oshi DC, Ezeoke ACY. Jaundice in pregnant
Nigerians. International Journal of=
Gynecology and Obstetrics 1999; 65(1): 59-60
=
8. Harry
TO, Bajani M.D, Moses A. Hepatitis B. Virus inf=
ection
among blood donors and pregnant women in Maiduguri, Nigeria. East Africa Medical Journal. 1994;=
7(8):596-7.
=
9. Amazigyo
UO, Chime AB. Hepatitis B virus infection in an urban population of Eastern
Nigeria: prevalence of serological markers. East
Afr Med. J. 1990; 67(8): 539-44.
=
10. Vildozola<=
/span> H, Baxil V, Canibilla=
E, Torres Y, Hora ME. Ramos E: prevalence of hepatitis B
infection and risk factors in two groups of pregnant adolescents related to=
the
number of sexual partners. Rev; Gastroenteral Pe=
ru
2006; 26(3): 242- 58
=
11. Saders RC, Lewis D=
, Dyke
T. Alpers MP. Markers of hepatitis B. infection in Tari District, southern =
Highland’s
province, Papa=
u New Guinea P. NH=
ighland’s
Journal. 1992; 35(3):197-2=
07.
=
12. Acquaye
J. K; Mingle Y. A. hepatitis B Virus markers in Ghanian pregnant women. West Afr J=
ournal
Med 1994; 13(3): 134 -7
=
13. Nelson=
NP,
Jamieson DJ, Murphy TV. Prevention of perinatal hepatitis B virus transmiss=
ion.
J Pediatric Infect Dis Soc. 2014; 3 Suppl 1: S7–12.
=
14. Anna S=
F, Lok MD.
Chronic hepatitis B. N Engl J Med. 2002; 346:1682–3.
=
15. McMaho=
n BJ,
Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute hepatit=
is B
virus infection: relation of age to the clinical expression of disease and
subsequent development of the carrier state. J Infect Dis. 1985;151(4):599–603.
16.
Lee C, Gong Y, Brok J, Boxall EH, G=
luud C.
Effect of hepatitis B immunisation in newborn infants of mothers positive f=
or
hepatitis B surface antigen: systematic review and meta-analysis. BMJ. 2006;33=
2(7537):328–36.
17.&=
nbsp; Ebonyi
State Government Nigeria. People and occupation. Available at: www.ebonyistate.gov.ng/profile.html,
Accessed 10th March 2021.
=
18. Araoye MO. Subjects
selection. In Araoye M.O=
span>
(ed) Research Methodology with Statistics for Health and social sciences llorin. Nathadax publish=
ers
2003:115-129.
=
19. Onakewhor, JUE, Offor=
E, Okonofua, FE, Maternal and neonatal sero-prevalence
of Hepatitis B surface antigen (HBsAg) in Benin City. Journal of Obst=
etrics
and Gynecology 2021;21 (6): 583-586.
=
20. Agbede OO., Iseniyi, JO, Kolawole MO, Ojuowa=
A. Risk factors and sero-prevalence of hepatiti=
s B
surface antigenemia in mothers and their preschool age children in Ilorin,
Nigeria. Therapy 2007;4(1): 67-72.
=
21. Harry
TO, Bajani MD, Moses AE. Hepatitis B virus infection among blood donors and
pregnant women in Maiduguri, Nigeria. East
Africa Medical Journal 1994; 7=
0:596-597.
=
22. Luka SA, Ibrahim, MB., Iliya, SN.
(2008). Seroprevalence
of hepatitis B surface antigen among pregnant women attending Ahmadu Bello
University Teaching hospital, Zaria, Nigeria. Nigerian Journal of Parasitology, 29(1): 38-41.
=
23. Ndams IS, Joshua =
IA, Luka
SA, Sadiq HO. Epidemiology of Hepatitis B infection Among Pregnant Women. S=
cience
World Journal 2008;3(3):5-8.
24.&=
nbsp; Itoua-Ngaporo A, Sapoulou=
span> MV,
Ibara JR, Iloki LH, Denis F. Prevalence of hepatitis B viral markers in a
population of pregnant women in Brazzaville (Congo). J Gynecol
Obstet Biol Reprod (Paris). 1995; 24(5):534–6.
=
25. Okoth =
F, Mbuthia
J, Gatheru Z, Murila F, Kanyingi F, Mugo F, et al. Seroprevalence of hepatiti=
s B
markers in pregnant women in Kenya. East Afr Me=
d J.
2006;83(9):485–93.
=
26. Makuwa=
M, Caron
M, Souquière S, Mal=
onga-Mouelet
G, Mahé A, Kazanji M. Prevalence and gen=
etic
diversity of hepatitis B and delta viruses in pregnant women in Gabon:
molecular evidence that hepatitis delta virus clade 8 originates from and is
endemic in central Africa. J Clin Microbiol. 20=
08; 46:754–6.
=
27. Nacro =
B, Dao B,
Dahourou H, Hien F, Charpentier-Gautier L, Meda N, et al. HBs antigen &=
nbsp; carrier
state in pregnant women in Bobo Dioulasso (Burkina Faso). Dakar Med 2000;45(2):188–90.
=
28. Mansour W, Bollahi MA, Hamed CT, Brichler S, Le Gal F, Ducancelle=
A, et al. Virological
and epidemiological features of hepatitis delta infection among blood donor=
s in
Nouakchott, Mauritania. J Clin Virol. 2012; 55:12–6.
=
29. Candotti D, Da=
nso
K, Allain JP. Maternofe=
tal transmission of hepatitis B virus =
genotype
E in Ghana, west Africa. J Gen Virol. 2007; 88:2686–95.<=
span
lang=3DEN-GB style=3D'font-size:12.0pt;font-family:"Times New Roman",serif'=
>
=
30. Tour&e=
acute;-Fall
AO, Dièye TN, Sall A, Diop M, Seck M, Diop S, et al. Residual risk of
transmission of HIV and HBV, in Senegalese national blood bank from 2003 to
2005. Transfus Clin Biol. 2009; 16:439–43.
=
31. Madzime S, Adem M,
Mahomed K, Woelk GB, Mudzamiri S, Williams MA. Hepatitis B virus infection
among pregnant women delivering at Harare Maternity Hospital, Harare Zimbab=
we,
1996 to 1997. Cent Afr J Med. 1999;45(8):195–8.<=
span
lang=3DEN-GB style=3D'font-size:12.0pt;font-family:"Times New Roman",serif'=
>
=
32. Imade GE, Sagay AS,Ugw=
u
BT, Thacher TD, Ford RW. Seroprevalence of Hepa=
titis
B and HIV infections in pregnant women in Nigeria. J Med Trop 2004; 6:15<=
/b>-21
33.&=
nbsp; Burk RD, Hwang LY, Ho GY, Shafritz
DA, Beasley RP. Outcome of perinatal hepatitis. B virus exposure is dependent on maternal virus load=
. J Infect Dis. 1994; 170:1418–23.
34.&=
nbsp; Eke AC, Eke UA, Okafor CI, Ezebi=
alu
IU, Ogbuagu C. Prevalence, correlates, and patt=
ern of
hepatitis B surface antigen in a low resource setting. Virol
J. 2011; 8:12.
35.&=
nbsp; Thio CL. Hepatitis B, and human immunodeficiency virus
coinfection. Hepatology. 2009;49=
b>(5Suppl):
S138–45.
Agboeze J, et
al - Hepatitis B Virus Seroprevalence and Perinatal Transmission